A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy (PALETTE).

Trial Profile

A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy (PALETTE).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Leiomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PALETTE
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Oct 2016 Results of a retrospective analysis from EORTC6204, EORTC62072 studies and additional clinical data from real life setting investigating the activity of pazopanib in vascular sarcomas, presented at the 41st European Society for Medical Oncology Congress
    • 12 Mar 2016 Pooled analysis of 2 studies (n=44), including this study and other trial (see CTP 700014308) were published in the Gynecologic Oncology.
    • 11 Mar 2016 Results from retrospective postmarketing surveillance (n=156) published in the Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top